iasusa cover art

All Episodes

iasusa — 515 episodes

#
Title
1

(June 9, 2026) IAS-USA Dialogue Series: Emerging Infections and Health Threats

2

1. Welcome and Introduction

3

2. Data to Decisions: The ART of Initial ART

4

5. Challenging Cases in Advanced HIV: Managing Opportunistic Infections and New Guidance on ART

5

6. Closing Remarks

6

3. Hepatitis B Dilemmas: Navigating HBV Risk in the Tenofovir-Sparing ART Era

7

4. Managing ARV Experienced Patients: I'd Rather Switch Than Fight!

8

(March 26, 2026) IAS-USA Dialogue Series: Emerging Infections and Health Threats

9

(HIV 2026 ATL) Key CROI 2026 Updates by Colleen F. Kelley, MD, MPH

10

(HIV 2026 ATL) STI Updates Current Trends in Treatment and Prevention by Jason E. Zucker, MD

11

(HIV 2026 ATL) Brain Health in Older Adults With HIV by Meredith Greene, MD

12

(HIV 2026 ATL) PrEP Updates New Long-Acting Injectables, Management Challenges, and Diagnostic Testing Dilemmas by ment Challenges, and Diagnostic Testing Dilemmas by Hyman Scott, MD, MPH

13

(HIV 2026 ATL) Cases in HIV Medicine Putting it all Together by Michael S. Saag, MD

14

(HIV 2026 ATL) Investigational Antiretroviral Drugs Injectables and Beyond by Rajesh T. Gandhi, MD

15

(HIV 2026 ATL) David Letterman as a Dermatologist Top 10 Skin Lesions You Should Know by Toby A. Maurer, MD

16

4. Updates on the Evolving Landscape of HIV Management in Pregnancy and Postpartum

17

9. SUDs in HIV Care: MOUD, Emerging Therapies, and PrEP in the Context of Stimulant Use

18

1. Welcome and Introductions

19

5. Key Updates From CROI 2026

20

7. Evolving Diabetes Care in PWH: Screening, Treatment, and the Rise of GLP-1 RA Therapies

21

6. Cases in the Clinic 2026: From Ragtime to Two Strangers

22

10. Immunizations for PWH: Efficacy, Safety, Evolving Recommendation

23

11. Closing Remarks

24

3. Optimizing Long-Acting Therapeutics in Practice: Real-World Considerations and Failure Management

25

8. Advances in HIV and STI Prevention: A 2026 Updat

26

2. Lifetime of Leadership Award Presented to Gerald H. Friedland, MD

27

RWCC Day 2: Rebecca Abelman - Hormones and Health The Menopausal Transition in Women With HIV

28

RWCC Day 2: Melanie Thompson - Screening for the Big Cs in HIV Care

29

RWWC Day 3: Henry Masur - HIV Associated OIs All Too Common Despite the Miraculous Advances in ART

30

RWWC Day 3: Welcome to Day 3

31

RWWC Day 3: Roy M. Gulick - Investigational Antiretroviral Drugs and Formulations

32

RWWC Day 3: Closing Remarks

33

RWWC Day 3: Sandra A Springer - Mastering the Clinical Triple Threat

34

RWCC Day 2: Caryn Morse - Aging With HIV Focus on Cognitive Impairment and Frailty

35

RWCC Day 2: Todd Brown - Metabolic Update 2025 Diabetes and CKM Syndrome

36

RWCC Day 1: Heather Hauck - HRSA Ryan White HIVAIDS Program Updates

37

RWCC Day 2: Michael Saag - Interactive ART Cases From the Clinic(ians) Case-Based Panel Discussion

38

RWCC Day 1: Khalil Ghanem - Preventing and Managing Syphilis in 2026

39

RWCC Day 1: Welcome and Introduction

40

RWCC Day 2: Roger Bedimo -No Mo FOMO

41

RWCC Day 2: Michael Saag - Welcome to Day 2

42

RWCC Day 1: Katharine J Bar - Update on the Cure From In Between Days to Just Like Heaven

43

RWWC Day 3: Christine M. Durand - HIV and Transplantation Practice and Possibilities

44

RWCC Day 2 Priscilla Y Hsue - 2025 Update on HIV and Cardiovascular Disease Lipids, Inflammation, and More

45

RWCC Day 1: Hyman Scott - Case-Based Approaches to Pre- and Postexposure Prophylaxis

46

“In Case You Missed It”: New Developments in HIV Prevention and Treatment

47

Closing Remarks

48

What Would You Do? Challenging Cases in HIV Management: Case-Based Panel Discussion

49

From DoxyPEP to Antimicrobial Resistance: The Changing Face of STIs

50

Be Prepared With PEP: Emergency Management of HIV, HBV, and HCV Exposures

51

Welcome and Introduction

52

HIV Vaccines in 2026 and Beyond: Promise and Persistence

53

Aging With HIV: How Not to Go Gently Into That Good Night

54

The Science of Aging: Epigenetics and Other Hallmarks of Aging

55

Immunization for Aging Adults With HIV: What’s New for the Old

56

Aging in the Context of HIV and Cancer: What Does “Age” Actually Mean?

57

Welcome and Introductions

58

Closing Remarks

59

HIV, Aging, and the Brain: A Practical Approach

60

From Fierce to Frail: Assessing Aging With HIV

61

Just Do It: Overcoming Clinical Inertia to Improve Heart Health

62

Update on the Cure: From In Between Days to Just Like Heaven

63

Closing Remarks

64

Beyond the Horizon: HIV Treatments in the Making

65

In Case You Missed It: Recent Changes in Guidelines, New Publications, & Updates

66

Aging with HIV: Optimizing Care for Older Adults

67

Welcome and Introduction

68

A Focused Update on Immunizations in People with HIV

69

Controversies in HIV Management: Case-Based Discussion

70

From Data to Action: Advances and Evolving Strategies in HIV and STI Prevention

71

(December 5, 2025) IAS-USA Dialogue Series: Emerging Infections and Health Threats

72

(August 13, 2025) Latest Update on Urgent Virus Outbreaks: Summer 2025

73

Chlamydia Management Updates: Advances and Vaccines Developments for STI Prevention

74

Latest Guidelines for Screening and Treatment for Human Papillomavirus and Anal Cancer

75

Welcome and Introduction

76

Preexposure Prophylaxis for HIV Infection: PrEP-Aring for The Next Decade

77

Preventing and Managing Syphilis in 2025

78

Updates on Hepatitis B Coinfection: Challenging Serology and Treatment Approaches

79

Drug-Resistant Gonorrhea: Epidemiology, Management, and Future Treatment

80

Closing Remarks

81

(May 13, 2025) Latest Update on Urgent Virus Outbreaks: Spring 2025

82

Ulcerative Sexually Transmitted Infections: Syphilis, Herpes Simplex Virus, Mpox, and Others

83

Updates on HIV Primary Care

84

Key Updates From CROI 2025

85

Year 13 of the Modern PrEP Era: A Spoon (Not a Fork) in the Road?

86

Weight Management and GLP-1 Receptor Agonists for People With HIV: Insights and Strategies

87

Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion

88

A Tough Nut to Crack? Update on Hepatitis B Cure

89

Next-Generation STI Prevention: DoxyPEP, CDC Guidelines, and the Gonorrhea Vaccine Debate

90

Treatment & Prevention of Syphilis in People With HIV, Addressing the Congenital Syphilis Epidemic

91

Anal Cancer Screening: Implementing Guidelines in the Real World

92

Challenging Cases in Antiretroviral Therapy and Panel Discussion

93

Gender-Affirming Hormone Initiation and Antiretroviral Therapy Considerations

94

PrEP Update: Long-Acting Agents and PrEP During Pregnancy

95

Update on HIV Primary Care: New Data, New Guidelines

96

Closing Remarks

97

CROI 2025 Insights To Treat, Per Chance to Cure HIV

98

Welcome and Introduction

99

(January 15, 2025) Latest Update on Urgent Virus Outbreaks: Winter 2025

100

HIV Prevention and STI Prevention -- Lead: Raphael J. Landovitz, MD

101

Substance Use Disorder and HIV -- Lead: Sandra A. Springer, MD

102

Comorbidities in the Setting of ART: Focus on Cardiovascular Disease, Statins, and Weight Management -- Leads: Melanie A. Thompson, MD, and Roger J. Bedimo, MD

103

When and What to Start -- Lead: Huldrych F. Günthard, MD

104

Closing Remarks -- Co-Chairs: Rejesh T. Gandhi, MD, and Michael S. Saag, MD

105

Welcome and Introduction -- Co-Chairs: Rejesh T. Gandhi, MD, and Michael S. Saag, MD

106

Coinfections in the Setting of ART: Tuberculosis, Opportunistic Infections, and Others -- Lead: Brenda E. Crabtree Ramírez, MD

107

When and How to Switch -- Lead: Rajesh T. Gandhi, MD

108

Comprehensive Overview: Latest Guidelines for Screening and Treatment for Human Papillomavirus and Anal Cancer -- Presenter: Timothy J. Wilkin, MD, MPH

109

Closing -- Co-Chairs: Henry Masur, MD and Michael S. Saag, MD

110

Treating and Preventing HIV: Updates From the IAS–USA Guidelines -- Presenter: Rajesh T. Gandhi, MD

111

Advancements in Long-Acting Drugs for HIV Treatment and Prevention, Including Emerging Therapies -- Presenter: Roy M. Gulick, MD, MPH

112

A Pound of Cure: Exploring the Potential Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) and Other Substance Use Treatments Beyond Opioids -- Presenter: Ellen F. Eaton, MD

113

Strategies to Reduce Cardiovascular Disease in Persons With HIV in 2024 – Where Do We Go From Here? -- Presenter: Priscilla Y. Hsue, MD

114

Welcome and Introductions -- Co-Chairs: Henry Masur, MD and Michael S. Saag, MD

115

Key Opportunistic Infections: Not Gone and Not Forgotten – Cases from the Clinic and Panel Discussion -- Presenter: Constance A. Benson, MD

116

Welcome (Day 2)

117

HIV and Aging: Focus on Neurocognitive Impairment -- Presenter: Meredith Greene, MD

118

Substance Use Disorder, HIV, and Mental Health -- Presenter: Karinn A. Glover, MD, MPH

119

Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion -- Presenter: Michael S. Saag, MD

120

Infections and Sexual Health – What’s New in Detection and Treatment: STI Updates From the Treatment Guidelines -- Presenter: Natalie Neu, MD, MPH

121

Diagnosis, Treatment, and Complications of Diabetes in People With HIV -- Presenter: Todd T. Brown, MD, PhD

122

Practice Changing Updates in the Primary Care Management of People With HIV -- Presenter: David H. Spach, MD

123

Comprehensive Review of Weight Loss Management -- Presenter: Zoobia W. Chaudhry, MBBS

124

From Cases to Care: Exploring Long-Acting HIV Therapies in Practice -- Presenter: Joshua P. Havens, PharmD

125

Top 10 Questions to the NCCC Warmline: What’s Coming Up for Providers Across the Country? -- Presenter: Carolyn Chu, MD, MSc

126

HIV Care: Successfully Navigating the Transition from Pediatric to Adult Care -- Presenter: Allison L. Agwu, MD, ScM

127

Shots, Shots, Shots: Updates on Oral and Injectable Preexposure Prophylaxis -- Presenter: Hyman Scott, MD, MPH

128

Welcome (Day 3)

129

New and Investigational Antiretroviral Drugs and Formulations: Transforming the Care of People with HIV -- Presenter: Rajesh T. Gandhi, MD

130

Patient Engagement in Care: Strategies to Inform Implementation Science and Practice -- Presenter: Michael J. Mugavero, MD, MHSc

131

‘Weighing’ the Clinical Benefits of Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) -- Presenter: Suman Srinivasa, MD, MS

132

HRSA Ryan White HIV/AIDS Program Updates -- Presenter: Laura W. Cheever, MD, ScM

133

Treatment and Prevention of Syphilis in People With HIV -- Presenter: Kimberly A. Workowski, MD

134

Welcome and Introduction (Day 1)

135

Dermatologic Manifestations of HIV -- Presenter: Toby Maurer, MD

136

(October 4, 2024) Latest Update on Urgent Virus Outbreaks: October 2024

137

Cryptococcal Meningitis State Of The Art For Diagnosis, Treatment, And Prevention 1

138

No Brainers Think Again OIs In Brain, Lungs, And Elsewhere

139

Opportunistic Infections Past, Present, What's New, & Review Of Guidelines

140

Pneumocystis What’s Old And What’s New

141

Treatment And Diagnosis Of Mycobacterium Avium Complex Disease

142

Welcome And Introductions

143

Closing Remarks

144

(June 11) Latest Update on Urgent Virus Outbreaks: June 2024

145

Welcome and introductions

146

State of the ART: Hot Antiretroviral Updates from CROI 2024 and Beyond

147

“Weighing In” on GLP-1 Receptor Agonists for People With HIV

148

The Latest Updates on Immunizations for People With HIV

149

Challenging Cases in Antiretroviral Therapy and Panel Discussion

150

Closing

151

Statins: Young at Heart

152

No Mo FOMO—In Case You Missed It: Recent Changes in Guidelines, New Publications and Conferences

153

The Art and Science of Prevention: Updates in HIV PrEP and Doxy-PEP

154

Welcome and Introductions

155

HIV Cure: Where Are We and Do We Have a Map?

156

Key Updates from CROI 2024

157

Managing Substance Use Disorders: Opioids, Stimulants, and Alcohol

158

Antiretroviral Therapy Cases From the Clinic(ians)

159

Sexually Transmitted Infections: Challenges in Management and Prevention

160

Reducing Cardiovascular Events in People With HIV: A Much-Needed REPRIEVE For an At-Risk Population

161

Hit Me With Your Best Shot! Routine Immunizations for People With HIV

162

Closing Remarks

163

(March 26, 2024) Latest Update on Urgent Virus Outbreaks: March 2024

164

Welcome and Introductions

165

From Data to Options: Advances in Sexually Transmitted Infection Prevention

166

Managing Substance Use Disorders: Opioids, Stimulants, and Alcohol

167

Key Updates from CROI 2024

168

Challenging Cases in Antiretroviral Therapy and Panel Discussion

169

Statins in the Post–REPRIEVE Era: Who, When, and Why

170

Hypertension and Cardiometabolic Issues in People With HIV: 2024 Update

171

“Weighing In” on GLP-1 Receptor Agonists for People With HIV

172

LA Agents for HIV Therapeutics and Prevention: Where We Are, Where We Aren’t, & Where We’re Going

173

Resistance in Long-Acting Therapy for Prevention and Treatment: Uncommon Outcome or Achilles Heel

174

Welcome and Introduction

175

Sex, Drugs, and ART: Addressing Substance Use in People with HIV

176

Preventing Heart Disease in People with HIV: Delivering REPRIEVE from a Major Comorbidity

177

“Weighing In” on GLP-1 Receptor Agonists for People With HIV

178

Updates in STI Prevention and Treatment: DoxyPEP and More

179

The Future of ART

180

Closing

181

State of the Science: What We Know about Long-Acting Injectable Agents for Treatment of HIV

182

State of the Science: What We Know about Long-Acting Injectable Agents for HIV Prevention

183

Annoying But Necessary: Navigating the Challenges of LA Treatment & Prevention Strategies

184

Welcome and Introduction

185

Closing Remarks

186

Challenging Cases in LA Treatment and Prevention: What Would You Do?

187

(October 19, 2023) Latest Update on Urgent Virus Outbreaks: October 2023

188

(August 1, 2023) Latest Update On Urgent Virus Outbreaks August 2023

189

Welcome and Introductions

190

Patient Perspective: Long COVID

191

Pathogenesis of Long COVID: Organicity and Mechanisms

192

Long COVID Diagnosis and Management: A Case-Based Panel Discussion

193

Long COVID and HIV

194

Long COVID Clinical Trials: Challenges and Opportunities

195

Closing

196

(June 15, 2023) A Conversation About Dispatches From the AIDS Pandemic: A Public Health Story

197

Welcome and Introduction

198

New and Investigational Antiretroviral Drugs and Formulations

199

In Case You Missed It: CROI 2023, Publications, and Guidelines

200

Challenging Cases in Antiretroviral Therapy and Panel Discussion

201

The Latest Updates on HIV Prevention

202

Treatment and Management of Syphilis and Gonorrhea

203

Managing Cardiovascular Disease in People with HIV

204

Primary Care for People with HIV: Immunizations

205

(February 2, 2023) Latest Issues in COVID-19: Vaccines, Long COVID, Prevention, and Pediatrics

206

(Apri 20,2023) Latest Update on Urgent Virus Outbreaks: April 2023

207

Welcome and Introductoin

208

Key Updates from CROI 2023

209

New and Investigational Antiretroviral Drugs and Formulations

210

Challenging Cases in Antiretroviral Therapy and Panel Discussion

211

Infant Feeding and People with HIV

212

Cardiovascular Disease and HIV

213

Managing Substance Use Disorders: Opioids, Stimulants, and Alcohol

214

Preexposure Prophylaxis

215

Managing Sexually Transmitted Infection: Doxycycline Postexposure Prophylaxis

216

Closing Remarks

217

New and Investigational Antiretroviral Drugs and New Strategies for HIV Management

218

Antiretroviral Therapy Cases From the Clinic(ians)

219

Managing Substance Use Disorders: Opioids, Stimulants, and Alcohol

220

Testing and Treating (and Preventing) Sexually Transmitted Infections in People With HIV

221

Latest Strategies in the Prevention of HIV

222

Long COVID: Diagnosis and Management

223

Closing

224

Welcome And Introduction

225

mRNA Vaccine Technology and the Prospects for an HIV Vaccine

226

Key Updated from CROI 2023

227

(March 21, 2023) Latest Update on Urgent Virus Outbreaks: March 2023

228

(January 9, 2023) Latest Update on Urgent Virus Outbreaks: COVID-19, RSV, and Influenza

229

Comorbidities In The Setting Of Antiretroviral Therapy

230

Recent Co-Infections In The Setting Of ART: MPX And COVID - 19

231

When And How To Switch

232

Substance Use Disorder

233

HIV Prevention And STI Screening And Prevention

234

Closing Remarks

235

Welcome And Introductions

236

When And What To Start

237

bNAbs: Where Are We Going?

238

In Case You Missed It: Updates From Recent Publications And Meetings

239

The Effect of the Pandemic on Ending the HIV Epidemic Initiative

240

Providing Gender Affirming Care

241

Closing Remarks

242

Welcome And Introductions

243

Antiretroviral Therapy Cases: HIV Prevention and Treatment

244

Anal Cancer Screening: What Now?

245

3.7.Closing

246

mRNA Vaccine Development for HIV Vaccines

247

New and Investigational Antiretroviral Drugs

248

Antiretroviral Therapy Cases From the Clinic(cians)

249

Providing Gender-Affirming Care

250

An Update on Hepatitis B Virus Infection

251

Management of AIDS-Related Opportunistic Infections

252

Methicillin-Resistant Straphylococcus aureus (MRSA) in PWH

253

Opioid Use Disorder

254

Urgent Emerging Infections in HIV: Monkeypox

255

Reducing Health Disparities Among Disparate Populations

256

Breast Feeding and Individuals With HIV

257

HIV Prevention From the Centers of Disease Control and Prevention Perspective

258

Current CDC STI Treatment Guidelines: An Update

259

HIV Practitioner Burnout Panel

260

(September 15, 2022) Continued Discussion on Urgent Virus Outbreaks: COVID-19, Monkeypox, and More

261

Aging And HIV

262

In Case You Missed It: The Latest in HIV Literature and Monkeypox

263

New And Investigational Drugs

264

Preexposure Prophylaxis

265

Recognizing And Managing Practitioner Burnout

266

Special Panel Session

267

Antiretroviral Therapy Cases From the Clinic(ians): A Case-Based Presentation and Panel Discussion

268

Welcome And Introductions

269

(August 23, 2022) Urgent Virus Outbreaks: COVID-19 and Monkeypox

270

Closing

271

Difficult Cases In Inpatient Care For COVID - 19

272

Difficult Cases In Prevention And Outpatient Care For COVID - 19

273

Post - COVID Complications

274

Roundtable Discussion

275

Welcome And Introductions

276

The Clinical Relationship Between HIV And COVID - 19

277

(July 7, 2022) COVID-19 Rebound, Subvariants BA.4 and BA.5, Vaccines, and More

278

Welcome And Introductions

279

The Revolution of MRNA Vaccines: Implications for an HIV Vaccine

280

CROI 2022 Review

281

New and Investigational Drugs for Treatment and Prevention

282

Challenges Cases in Antiretroviral Therapy and Panel Discussion

283

The Clinical Relationship Between HIV and COVID-19

284

Special Panel Session: 40 Years Later

285

(June 7, 2022) Detailed Discussion on COVID-19 Vaccines, Boosters, Therapeutics, Variants, and More

286

(May 6, 2022) COVID-19 Therapeutics, 2nd Booster, Variants of Variants, and COVID-19 in Children

287

Controversies In Managing Sexually Transmitted Infections: A Case-Based Panel Discussion

288

Frailty Screening Preventing And Intervening

289

Optimizing Preexposure Prophylaxis

290

Screening For Anal Cancer: When to Screen and What to Do With the Results

291

Welcome And Introductions

292

Special Panel 40 Years Later: Looking Back at the Beginning of the HIV/AIDS Epidemic in Atlanta, GA

293

(April 1, 2022) The Latest on Omicron Subvariant BA.2 in the US, 4th Dose, and Vaccine in Children

294

Antiretroviral Therapy Cases From the Clinic(ians): A Case-Based Presentation and Panel Discussion

295

In Case You Missed It: Updates From CROI 2022 and Beyond

296

(February 4, 2022) Latest Update on COVID-19 Vaccines and Scientific Leaders’ Perspectives

297

Welcome

298

Investigational Antiretroviral Drugs and Strategies

299

COVID-19 Interactions with Other Viruses

300

Current Options for Treating and Managing COVID-19

301

Updated CDC Guidelines on Testing and Treating Sexually Transmitted Infections

302

State-of-the-art Cases on Antiretroviral Therapy

303

In Case You Missed It: Updates From Recent Publications and Meetings

304

Expert Roundtable Discussion

305

(December 3, 2021) Omicron Variant, Therapeutics, and COVID-19 in People Who Are Immunocompromised

306

Welcome

307

PrEP: State of the Science Overview

308

Strategies to Optimize PrEP: Schedules, Formulations, and Innovative Approaches

309

Assessing and Monitoring Persons Interested in Starting and Continuing PrEP

310

Question-and Answer Panel Session

311

Ending the HIV Epidemic: The Impact of PrEP

312

How to Reach the Hard to Reach: Policies and Strategies to Address Access to PrEP

313

Leveraging Administrative and Governmental Policies to Improve PrEP Utilization

314

Expert Roundtable Discussion

315

Closing

316

(October 22, 2021) COVID-19 in People Who Are Immunocompromised, Waning Immunity, Breakthrough...

317

Assessing Frailty in Older People With HIV

318

Neurocognition and the Aging Brain

319

Cardiovascular Disease in HIV: Moving From Insights to Interventions

320

Identifying, Managing, and Preventing Polypharmacy in Older People With HIV

321

Primary Care Concerns for the Aging Population

322

Expert Roundtable Discussion

323

SARS-CoV-2 Variants: Where Did They Come From and Where Are They Going (June 18, 2021)

324

Up to Date on COVID-19: Expert Discussion (June 1, 2021)

325

Challenges and Opportunities in Providing Remote HIV, STI, and COVID-19 Testing and Services

326

Challenges and Opportunities for Preexposure Prophylaxis

327

Vaccine Prevention for Individuals With HIV in the Era of COVID-19

328

HIV and COVID-19: Impact on Susceptibility, Disease, and Long-term Complications

329

Preventing Severe COVID-19: The Role of Monoclonal Antibodies and Beyond

330

Panel Discussion

331

Update From vCROI 2021

332

Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion

333

Challenges and Opportunities for Preexposure Prophylaxis

334

Management and Prevention of Sexually Transmitted Infections

335

Immunology and Pathogenesis of COVID-19

336

Long COVID-19: Long-Term Complications of COVID-19

337

Current Antiretroviral Drugs and Strategies for HIV Management

338

Investigational Antiretroviral Drugs for HIV

339

Collateral Damage of COVID-19 onHIVPatient Care

340

Current Status of COVID-19 TreatmentOptions for Mild, Moderate, and Severe Disease

341

Aging and Frailty in People With HIV

342

Drug-Drug Interactions and Polypharmacyin HIV: Case-Based

343

HIV Stigma and Unreached Populations

344

Challenges and Success in PrEP Implementation

345

Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion

346

Long-Acting Antiretroviral Drug Formulations for Treatment and Preventionof HIV

347

Update on Early Treatment of COVID-19 (April 13, 2021)

348

Latest on “COVID-19 Meets HIV”: Variants, Vaccines, and Health Disparities (February 10, 2021)

349

Update on New Strategies for Antiretroviral Therapy

350

Challenges and Opportunities for Preexposure Prophylaxis

351

Aging and Frailty in People With HIV

352

Long COVID-19: The Long-Term Complications of COVID-19

353

Neurologic Complications of COVID-19

354

The Inexorable Advancement to Long-Acting Antiretrovirals: To Jupiter and Beyond!

355

Update on SARS-CoV-2 Variants, Vaccine Development, and Decreasing the Case Rate (January 29, 2021)

356

Update on COVID-19 Vaccines (January 4, 2021)

357

Impact of the COVID-19 on HCV and STIs (November 23, 2020)

358

Update From Our Nation’s Capital, ID Week, and OI Guidelines

359

PrEP in the Era of COVID-19: A Case-Based Discussion

360

Projected Health Policy Changes in 2021

361

Update on the Clinical Management of HIV: A Case-Based Discussion

362

Where We Stand Today on a SARS-CoV-2 Vaccine

363

Antiretroviral Therapy: When and What to Start

364

When and How to Switch ART Regimens

365

Ending the HIV Epidemic

366

Laboratory Monitoring in Individuals With HIV

367

Prevention of HIV Infection

368

COVID-19 Update: Including the Intersection of HIV

369

Aging and HIV: Polypharmacy, Frailty, and Neurocognition

370

Lessons From the Lab: Implications for Coronavirus Vaccine and Therapeutics (October 19, 2020)

371

Addressing Questions About COVID-19 (September 23, 2020)

372

HIV and COVID-19 Interactions and Parallels in Advocacy (September 15, 2020)

373

New Strategies and Challenges of PrEP in the COVID-19 Era (September 9, 2020)

374

Continued Discussion on COVID-19 Epidemiology and Transmission (August 19, 2020)

375

Investigational New Antiretroviral Drugs and Strategies

376

Interactive Antiretroviral Therapy Cases

377

COVID-19: Update on Therapy and Vaccine Research

378

Preexposure Prophylaxis: Cases and Common Questions

379

HIV and Opioid Use: The Intersection of the Co-Epidemics in the Midwest

380

Current Status of COVID-19 Treatment and Vaccine Research (July 31, 2020)

381

Insights From AIDS 2020/COVID-19 at IAS, Updates on COVID-19... (July 22, 2020)

382

Update From IAS 2020

383

Interactive Antiretroviral Cases From the Clinic(ians) and Panel Discussion

384

Multidimensional Challenge of COVID-19, Including COVId-19 and HIV

385

Preexposure Prophylaxis: Cases and Commom Questions

386

Why COVID-19 Will Not Mean the End of the STI Epidemic (and May Make It Worse)

387

COVID-19 Meets HIV: Focus on Health Disparities (June 30, 2020)

388

Common Preexposure Prophylaxis Questions: A Cased-Based Presentation

389

What's Known About the Intersection of COVID-19 and HIV Infection

390

The Current Status on Treatment and Vaccines

391

Controlling the Spread of Infectious Diseases: Best Practices

392

New Antiretroviral Drugs and Strategies

393

Interactive Antiretroviral Therapy Cases and Panel Discussion

394

COVID-19 in Women (June 17, 2020)

395

COVID-19 Public Health Updates (June 10, 2020)

396

Ending the HIV Epidemic: Reaching the Unsuppressed and Out of Care Panel Discussion

397

Cardiovascular Diseases in HIV

398

Inflammation and Its Role in HIV Pathogenesis and Aging

399

Fri - Horn

400

Renal Disease and Kidney Transplant

401

Common PrEP Questions: A Case-Based Discussion

402

Neurocognitive Disorders in HIV

403

Ending the HIV Epidemic: Reaching the Unsuppressed and Out of Care Panel Discussion

404

Sexually Transmitted Infections on the Rise: Syphilis, Chlamydia, and Gonorrhea

405

Antiretroviral Therapy and Pregnancy in 2019: Current Recommendations and Controversies

406

Opioid Use and Substance Abuse Disorder

407

HRSA's HIV/AIDS Bureau Updates

408

Investigational Approaches to Antiretroviral Therapy

409

Treating HIV in 2019: Interactive Cases From the Clinic(ians) and Panel Discussion

410

Best Practices in HIV Care: Providing Gender Affirming Care for Transgender and Nonbinary People

411

Initiating Antiretroviral Therapy: What to Start and How to Monitor

412

Fundamentals of Antiretroviral Therapy

413

Sexual Health in Adolescents

414

Immunoprotection in HIV and Sexually Transmitted Infections

415

Sexually Transmitted Infections: The National Perspective

416

Sexually Transmitted Infections: The Local Perspective

417

Antiretroviral Therapy (ART) in Conception and Pregnancy in Women With HIV

418

Interactive Case-Based Panel Discussion: PrEP, STIs, and Sexual Health

419

Preexposure Prophylaxis: Current State of the Art

420

Syphilis: Reemergence of the Great Pretender?

421

Aging With HIV: I’ve Fallen But I Can Get Back Up

422

HIV Cure: Fact or Fiction

423

CROI 2019 Update on Tuberculosis and Other Opportunistic Infections

424

Investigational Approaches to Antiretroviral Therapy

425

CROI 2019: ARV for Prevention and Treatment, HIV Pathogenesis, and Cure

426

The Data-Free Zone: Tough Cases in HIV Prevention and STI Management

427

Interactive ART Cases From the Clinic(ians): Case-Based Panel Discussion

428

Sexually Transmitted Infections: Burning Issues

429

Infectious and Other Complications of Immunobiologic Agents Used by Individuals With HIV Infection

430

Update From the 2019 Conference on Retroviruses and Opportunistic Infections

431

Investigational Approaches to Antiretroviral Therapy

432

Interactive ART Case-Based Panel Discussion

433

Be Prepped for PrEP: Case-Based Discussion and PrEP in the Future

434

Is Hepatitis B Curable?

435

Addiction And HIV In 2019 What You Need To Know To Care For Your Patient

436

Chronic Pain In People Living With HIV Infection A Practical, Evidence - Based Approach

437

Immune Reconstitution Inflammatory Syndrome (IRIS) In HIV Infection Beyond What Meets The Eye

438

New Antiretroviral Strategies And Drugs

439

Sexually Transmitted Infections Cases From The Clinic(ians)

440

Treating And Preventing HIV In 2019 Interactive Cases From The Clinic(ians)

441

What’s New In Opportunistic Infections And…Washington DC

442

Addiction and HIV in 2019: What You Need to Know to Care for Your Patients

443

Top 10 Updates in Viral Hepatitis for the HIV Practitioner

444

Common PrEP Questions: A Case-Based Panel Discussion

445

Interactive ART Cases From the Clinic: Is There One Right Answer?

446

New Drugs and Novel Strategies for Antiretroviral Therapy

447

Update From CROI 2019: Ending AIDS by 2030

448

Infectious and Other Complications of Immunobiologic Agents Used by Individuals With HIV Infection

449

Advances Toward A Cure For HIV Getting Beyond N = 1 2

450

Common PrEP Questions A Case - Based Discussion

451

HIV And Liver Disease

452

Interactive ART Cases From The Clinic(ians) Case - Based Panel Discussion

453

New Drugs In Development Are We Ready For Long - Acting ART

454

Sexually Transmitted Infections

455

Management Of Comorbidities In Older Adults With HIV Infection

456

ART In Women And Pregnancy InSTIs, Comorbid Conditions, And Other Current Issues

457

Interactive PrEP Cases And Discussion

458

Interactive ART Cases From The Clinic(ians) Case - Based Panel Discussion

459

Update From The 2019 Conference On Retroviruses And Opportunistic Infections

460

Therapeutic HIV Vaccines and Broadly Neutralizing Antibodies

461

HIV Disease Management Course Overview

462

Audience Cases and Discussion: “I have a patient who…”

463

Cases: Treatment of and Monitoring for Hepatitis C in Patients with Cirrhosis

464

Cases: Management of Hepatitis C in Prior Treatment Failure

465

Cases: Issues in Hepatitis C in Active or Recently Active Substance Abuse and Renal Failure

466

Cases: Initial Treatment of Hepatitis C

467

Management of Liver Diseases: A Nonhepatologist’s Viewpoint

468

Hepatitis C: Introduction and Overview

469

Overview of Hepatitis C in South Carolina

470

Welcome and Participant Introductions

471

Audience Cases and Discussion: “I have a patient who…”

472

Cases: Treatment of Hepatitis C in Patients with Cirrhosis and Advanced Liver Disease

473

Cases: Management of Hepatitis C in Prior Treatment Failure

474

Cases: Initial Treatment of Hepatitis C

475

Hepatology for the Nonhepatologist

476

Hepatitis C in 2018: From Evolution to Revolution

477

Welcome and Participant Introductions

478

Audience Cases and Discussion: “I have a patient who…..”

479

Cases: Treatment of Hepatitis C in Patients with Cirrhosis and Advanced Liver Disease

480

Cases Management Of Hepatitis C In Prior Treatment Failure

481

Cases: Issues in Hepatitis C in Active or Recently Active Substance Abuse and Renal Failure

482

Cases: Initial Hepatitis C Treatment, Including Coinfection

483

Hepatology for the Nonhepatologist

484

Hepatitis C in 2018: From Evolution to Revolution

485

Welcome, Introductions, and Overview

486

Cases: Treatment of and Monitoring for Hepatitis C in Patients with Cirrhosis

487

Cases: Management of Hepatitis C in Prior Treatment Failure

488

Cases: Initial Treatment of Hepatitis C: Key Populations

489

Cases: Treatment of Hepatitis C in HIV/HCV Coinfection

490

Cases: Initial Treatment of Hepatitis C

491

Hepatology for the Nonhepatologist

492

Viva La Revolución: Options to Combat Hepatitis C

493

HIV, Hepatitis C, and Opioid Abuse: A Tennessee Tale

494

Welcome and Participant Introductions

495

Audience Cases and Discussion: “I have a patient who…”

496

Cases: Post-SVR Care and Monitoring

497

Cases: Management of HCV in Prior Treatment Failure

498

Cases: Initial Treatment of the Hepatitis C Virus-Infected Patient

499

End-Stage Liver Disease (ESLD): A Guide for HIV Physicians

500

Hepatitis C Introduction and Overview

501

Welcome, Introductions, and Overview

502

Opioid Withdrawal, Opioid Substitution, and HIV Infection

503

HIV and Cardiovascular Disease: Epidemiology, Mechanisms, and Clinical Implications

504

New Advances in HIV Prevention and Sexual Health

505

Microbes in the Middle: Understanding How the Human Microbiome Interacts with HIV

506

Antiretroviral Therapy – Cases From the Clinic (ians): Interactive Case-Based Panel Discussion

507

Investigational Approaches to Antiretroviral Therapy: New Strategies and Novel Agents

508

CROI 2018: What You Need to Know

509

Infectious and Other Complications of Immunobiologic Agents Used by HIV-Infected Individuals

510

Welcome to the IAS–USA Annual Update on HIV Disease Management

511

Top 10 Updates in Liver Care for the HIV Provider

512

Transgender Health and HIV Infection

513

Primary Care of the HIV-Infected Adult: If I Can Do It, You Can Do It

514

Antiretroviral Therapy (ART) Strategies: Interactive Case-Based Panel Discussion

515

Going With Your Gut: The Microbiome and You